77
Participants
Start Date
December 21, 2022
Primary Completion Date
January 3, 2024
Study Completion Date
January 31, 2024
Zabedosertib (BAY1834845)
Oral administration, two times a day
Placebo to zabedosertib (BAY1834845)
Oral administration, two times a day
Charité - Universitätsmedizin Berlin, Berlin
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
A.O.U. di Ferrara, Ferrara
University of Cincinnati College of Medicine - Dermatology, Cincinnati
Clinique Bezannes, Bezannes
Hautarztpraxis Prof. Dr. med. Christian Termeer, Stuttgart
Hôpital Saint Louis, Paris
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania, Catania
"NorthShore University HealthSystem , Skokie Hospital - Dermatology Department"
Beth Israel Deaconess Medical Center - Dermatology, Boston
"Arlington Research Center, Inc. , Arlington, TX"
Dermamedica s.r.o., Náchod
Clintrial s.r.o., Prague
Praglandia, Prague
"Centre Hospitalier Universitaire Nice , L'Archet Hospital - Dermatology Department"
"Humanitas Research Hospital , Cardio Center - Clinical, Interventional Cardiology and Coronary Care"
Dermal NZOZ Sp Osrodek Dermatologiczny Bialystok-Podlasie, Bialystok
Centrum Nowoczesnych Terapii Dobry Lekarz, Krakow
Santa Sp. z o.o., Lodz
Royalderm Agnieszka Nawrocka, Warsaw
Whipps Cross University Hospital - Clinical Research Unit, Leytonstone
Medicines Evaluation Unit, Wythenshawe
Lead Sponsor
Bayer
INDUSTRY